ID   PFKAL_HUMAN             Reviewed;         780 AA.
AC   P17858; Q96A64; Q96IH4; Q9BR91;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   06-MAR-2007, sequence version 6.
DT   10-MAY-2017, entry version 203.
DE   RecName: Full=ATP-dependent 6-phosphofructokinase, liver type {ECO:0000255|HAMAP-Rule:MF_03184};
DE            Short=ATP-PFK {ECO:0000255|HAMAP-Rule:MF_03184};
DE            Short=PFK-L;
DE            EC=2.7.1.11 {ECO:0000255|HAMAP-Rule:MF_03184};
DE   AltName: Full=6-phosphofructokinase type B;
DE   AltName: Full=Phosphofructo-1-kinase isozyme B;
DE            Short=PFK-B;
DE   AltName: Full=Phosphohexokinase {ECO:0000255|HAMAP-Rule:MF_03184};
GN   Name=PFKL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT TRP-151.
RC   TISSUE=Liver;
RX   PubMed=2533063; DOI=10.1089/dna.1989.8.733;
RA   Levanon D., Danciger E., Dafni N., Bernstein Y., Elson A., Moens W.,
RA   Brandeis M., Groner Y.;
RT   "The primary structure of human liver type phosphofructokinase and its
RT   comparison with other types of PFK.";
RL   DNA 8:733-743(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-81.
RX   PubMed=2139864; DOI=10.1016/0888-7543(90)90517-X;
RA   Elson A., Levanon D., Brandeis M., Dafni N., Bernstein Y.,
RA   Danciger E., Groner Y.;
RT   "The structure of the human liver-type phosphofructokinase gene.";
RL   Genomics 7:47-56(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Kidney, Lung, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 2-10 (ISOFORM 1).
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-10; 17-35 AND 185-210, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Prostatic carcinoma;
RA   Bienvenut W.V., Gao M., Leug H., Pchelintsev N., Adams P.D.;
RL   Submitted (JUL-2009) to UniProtKB.
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-775, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, GLYCOSYLATION AT
RP   SER-529, AND MUTAGENESIS OF THR-527 AND SER-529.
RX   PubMed=22923583; DOI=10.1126/science.1222278;
RA   Yi W., Clark P.M., Mason D.E., Keenan M.C., Hill C., Goddard W.A. III,
RA   Peters E.C., Driggers E.M., Hsieh-Wilson L.C.;
RT   "Phosphofructokinase 1 glycosylation regulates cell growth and
RT   metabolism.";
RL   Science 337:975-980(2012).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Catalyzes the phosphorylation of D-fructose 6-phosphate
CC       to fructose 1,6-bisphosphate by ATP, the first committing step of
CC       glycolysis. {ECO:0000255|HAMAP-Rule:MF_03184,
CC       ECO:0000269|PubMed:22923583}.
CC   -!- CATALYTIC ACTIVITY: ATP + D-fructose 6-phosphate = ADP + D-
CC       fructose 1,6-bisphosphate. {ECO:0000255|HAMAP-Rule:MF_03184,
CC       ECO:0000269|PubMed:22923583}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Allosterically activated by ADP, AMP, or
CC       fructose 2,6-bisphosphate, and allosterically inhibited by ATP or
CC       citrate. GlcNAcylation by OGT overcomes allosteric regulation.
CC       {ECO:0000255|HAMAP-Rule:MF_03184, ECO:0000269|PubMed:22923583}.
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; D-glyceraldehyde 3-
CC       phosphate and glycerone phosphate from D-glucose: step 3/4.
CC       {ECO:0000255|HAMAP-Rule:MF_03184}.
CC   -!- SUBUNIT: Homo- and heterotetramers. Muscle is M4, liver is L4, and
CC       red cell is M3L, M2L2, or ML3.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-487243, EBI-487243;
CC       Q969Y2:GTPBP3; NbExp=3; IntAct=EBI-487243, EBI-740290;
CC       P60409:KRTAP10-7; NbExp=3; IntAct=EBI-487243, EBI-10172290;
CC       P26371:KRTAP5-9; NbExp=3; IntAct=EBI-487243, EBI-3958099;
CC       P08237:PFKM; NbExp=6; IntAct=EBI-487243, EBI-514788;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_03184}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P17858-1; Sequence=Displayed;
CC       Name=2; Synonyms=a;
CC         IsoId=P17858-2; Sequence=VSP_011854;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: GlcNAcylation at Ser-529 by OGT decreases enzyme activity,
CC       leading to redirect glucose flux through the oxidative pentose
CC       phosphate pathway. Glycosylation is stimulated by both hypoxia and
CC       glucose deprivation. {ECO:0000269|PubMed:22923583}.
CC   -!- MISCELLANEOUS: In human PFK exists as a system of 3 types of
CC       subunits, PFKM (muscle), PFKL (liver) and PFKP (platelet)
CC       isoenzymes.
CC   -!- MISCELLANEOUS: Glycosylation may play a role in cancer cell
CC       proliferation: inhibition of 6-phosphofructokinase activity and
CC       subsequent redirection of the glucose flux through the oxidative
CC       pentose phosphate pathway confers a selective growth advantage on
CC       cancer cells. Moreover GlcNAcylation is observed in multiple
CC       cancer cell lines and tissue samples and GlcNAcylation leads to
CC       larger xenografts tunors in mice (PubMed:22923583).
CC       {ECO:0000305|PubMed:22923583}.
CC   -!- SIMILARITY: Belongs to the phosphofructokinase type A (PFKA)
CC       family. ATP-dependent PFK group I subfamily. Eukaryotic two domain
CC       clade "E" sub-subfamily. {ECO:0000255|HAMAP-Rule:MF_03184}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X15573; CAA33597.1; -; mRNA.
DR   EMBL; X16911; CAB46744.1; -; Genomic_DNA.
DR   EMBL; X16912; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16913; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16914; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16915; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16916; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16917; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16918; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16919; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16920; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16921; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16922; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16923; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16924; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16925; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16926; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16927; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16928; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16929; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; X16930; CAB46744.1; JOINED; Genomic_DNA.
DR   EMBL; AP001754; BAA95561.1; -; Genomic_DNA.
DR   EMBL; BC006422; AAH06422.1; -; mRNA.
DR   EMBL; BC007536; AAH07536.1; -; mRNA.
DR   EMBL; BC008964; AAH08964.1; -; mRNA.
DR   EMBL; BC009919; AAH09919.1; -; mRNA.
DR   CCDS; CCDS33582.1; -. [P17858-1]
DR   PIR; A33639; A33639.
DR   RefSeq; NP_001002021.2; NM_001002021.2.
DR   RefSeq; NP_002617.3; NM_002626.5. [P17858-1]
DR   UniGene; Hs.255093; -.
DR   ProteinModelPortal; P17858; -.
DR   SMR; P17858; -.
DR   BioGrid; 111232; 56.
DR   IntAct; P17858; 21.
DR   MINT; MINT-5004093; -.
DR   STRING; 9606.ENSP00000269848; -.
DR   iPTMnet; P17858; -.
DR   PhosphoSitePlus; P17858; -.
DR   SwissPalm; P17858; -.
DR   BioMuta; PFKL; -.
DR   DMDM; 134048493; -.
DR   EPD; P17858; -.
DR   MaxQB; P17858; -.
DR   PaxDb; P17858; -.
DR   PeptideAtlas; P17858; -.
DR   PRIDE; P17858; -.
DR   TopDownProteomics; P17858-1; -. [P17858-1]
DR   DNASU; 5211; -.
DR   Ensembl; ENST00000349048; ENSP00000269848; ENSG00000141959. [P17858-1]
DR   GeneID; 5211; -.
DR   KEGG; hsa:5211; -.
DR   UCSC; uc002zel.4; human. [P17858-1]
DR   CTD; 5211; -.
DR   DisGeNET; 5211; -.
DR   GeneCards; PFKL; -.
DR   H-InvDB; HIX0016166; -.
DR   HGNC; HGNC:8876; PFKL.
DR   HPA; HPA030047; -.
DR   MIM; 171860; gene.
DR   neXtProt; NX_P17858; -.
DR   OpenTargets; ENSG00000141959; -.
DR   PharmGKB; PA33215; -.
DR   eggNOG; KOG2440; Eukaryota.
DR   eggNOG; COG0205; LUCA.
DR   GeneTree; ENSGT00390000013209; -.
DR   HOGENOM; HOG000200154; -.
DR   HOVERGEN; HBG000976; -.
DR   InParanoid; P17858; -.
DR   KO; K00850; -.
DR   OMA; RTYSHLN; -.
DR   OrthoDB; EOG091G01YN; -.
DR   PhylomeDB; P17858; -.
DR   TreeFam; TF300411; -.
DR   BioCyc; MetaCyc:HS06881-MONOMER; -.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   SABIO-RK; P17858; -.
DR   UniPathway; UPA00109; UER00182.
DR   ChiTaRS; PFKL; human.
DR   GeneWiki; PFKL; -.
DR   GenomeRNAi; 5211; -.
DR   PMAP-CutDB; P17858; -.
DR   PRO; PR:P17858; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; ENSG00000141959; -.
DR   CleanEx; HS_PFKL; -.
DR   ExpressionAtlas; P17858; baseline and differential.
DR   Genevisible; P17858; HS.
DR   GO; GO:0005945; C:6-phosphofructokinase complex; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0003872; F:6-phosphofructokinase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0070061; F:fructose binding; IDA:BHF-UCL.
DR   GO; GO:0070095; F:fructose-6-phosphate binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0061621; P:canonical glycolysis; TAS:Reactome.
DR   GO; GO:0030388; P:fructose 1,6-bisphosphate metabolic process; IDA:UniProtKB.
DR   GO; GO:0006002; P:fructose 6-phosphate metabolic process; IDA:UniProtKB.
DR   GO; GO:0006096; P:glycolytic process; IDA:UniProtKB.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0051289; P:protein homotetramerization; IEA:Ensembl.
DR   GO; GO:0051259; P:protein oligomerization; IDA:BHF-UCL.
DR   GO; GO:0009749; P:response to glucose; IDA:UniProtKB.
DR   HAMAP; MF_03184; Phosphofructokinase_I_E; 1.
DR   InterPro; IPR009161; 6-Pfructokinase_euk.
DR   InterPro; IPR022953; ATP_PFK.
DR   InterPro; IPR015912; Phosphofructokinase_CS.
DR   InterPro; IPR000023; Phosphofructokinase_dom.
DR   Pfam; PF00365; PFK; 2.
DR   PIRSF; PIRSF000533; ATP_PFK_euk; 1.
DR   PRINTS; PR00476; PHFRCTKINASE.
DR   SUPFAM; SSF53784; SSF53784; 2.
DR   TIGRFAMs; TIGR02478; 6PF1K_euk; 1.
DR   PROSITE; PS00433; PHOSPHOFRUCTOKINASE; 2.
PE   1: Evidence at protein level;
KW   Acetylation; Allosteric enzyme; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Direct protein sequencing; Glycolysis;
KW   Glycoprotein; Kinase; Magnesium; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.6}.
FT   CHAIN         2    780       ATP-dependent 6-phosphofructokinase,
FT                                liver type.
FT                                /FTId=PRO_0000112021.
FT   NP_BIND      88     89       ATP. {ECO:0000255|HAMAP-Rule:MF_03184}.
FT   NP_BIND     118    121       ATP. {ECO:0000255|HAMAP-Rule:MF_03184}.
FT   REGION        2    390       N-terminal catalytic PFK domain 1.
FT   REGION      164    166       Substrate binding. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   REGION      208    210       Substrate binding. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   REGION      298    301       Substrate binding. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   REGION      391    400       Interdomain linker.
FT   REGION      401    780       C-terminal regulatory PFK domain 2.
FT   REGION      527    531       Allosteric activator fructose 2,6-
FT                                bisphosphate binding. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   REGION      572    574       Allosteric activator fructose 2,6-
FT                                bisphosphate binding. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   REGION      660    663       Allosteric activator fructose 2,6-
FT                                bisphosphate binding. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   ACT_SITE    166    166       Proton acceptor. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   METAL       119    119       Magnesium; catalytic. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   BINDING      25     25       ATP; via amide nitrogen.
FT                                {ECO:0000255|HAMAP-Rule:MF_03184}.
FT   BINDING     201    201       Substrate; shared with dimeric partner.
FT                                {ECO:0000255|HAMAP-Rule:MF_03184}.
FT   BINDING     264    264       Substrate. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   BINDING     292    292       Substrate; shared with dimeric partner.
FT                                {ECO:0000255|HAMAP-Rule:MF_03184}.
FT   BINDING     470    470       Allosteric activator fructose 2,6-
FT                                bisphosphate. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   BINDING     565    565       Allosteric activator fructose 2,6-
FT                                bisphosphate; shared with dimeric
FT                                partner. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   BINDING     628    628       Allosteric activator fructose 2,6-
FT                                bisphosphate. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   BINDING     654    654       Allosteric activator fructose 2,6-
FT                                bisphosphate; shared with dimeric
FT                                partner. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   BINDING     734    734       Allosteric activator fructose 2,6-
FT                                bisphosphate. {ECO:0000255|HAMAP-
FT                                Rule:MF_03184}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.6}.
FT   MOD_RES     377    377       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P47858}.
FT   MOD_RES     640    640       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P12382}.
FT   MOD_RES     775    775       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   CARBOHYD    529    529       O-linked (GlcNAc) serine.
FT                                {ECO:0000269|PubMed:22923583}.
FT   VAR_SEQ       1     28       MAAVDLEKLRASGAGKAIGVLTSGGDAQ -> MCNQGRGRE
FT                                SSRGGLHVQGSCRGLSRSPQQETGFAKAPAGTDCFFHCSPG
FT                                SRGQGDRKEEVTSEPGGTSIMSRLG (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_011854.
FT   VARIANT      81     81       G -> A. {ECO:0000269|PubMed:2139864}.
FT                                /FTId=VAR_006070.
FT   VARIANT     151    151       R -> W (in dbSNP:rs755851304).
FT                                {ECO:0000269|PubMed:2533063}.
FT                                /FTId=VAR_006071.
FT   VARIANT     237    237       D -> V (in dbSNP:rs1057037).
FT                                /FTId=VAR_030872.
FT   MUTAGEN     527    527       T->A: Does not affect GlcNAcylation.
FT                                {ECO:0000269|PubMed:22923583}.
FT   MUTAGEN     529    529       S->A: Prevents GlcNAcylation and enhance
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:22923583}.
FT   CONFLICT     27     27       A -> R (in Ref. 1; CAA33597 and 2;
FT                                CAB46744). {ECO:0000305}.
FT   CONFLICT     86     86       S -> T (in Ref. 2; CAB46744).
FT                                {ECO:0000305}.
FT   CONFLICT     89     89       C -> S (in Ref. 1; CAA33597 and 2;
FT                                CAB46744). {ECO:0000305}.
FT   CONFLICT    103    103       Y -> N (in Ref. 2; CAB46744).
FT                                {ECO:0000305}.
FT   CONFLICT    236    236       E -> EAPPE (in Ref. 2; CAB46744).
FT                                {ECO:0000305}.
FT   CONFLICT    386    386       K -> R (in Ref. 2; CAB46744).
FT                                {ECO:0000305}.
FT   CONFLICT    389    389       A -> T (in Ref. 1; CAA33597 and 2;
FT                                CAB46744). {ECO:0000305}.
FT   CONFLICT    648    648       K -> N (in Ref. 4; AAH08964/AAH09919).
FT                                {ECO:0000305}.
FT   CONFLICT    717    717       V -> A (in Ref. 4; AAH08964/AAH09919).
FT                                {ECO:0000305}.
SQ   SEQUENCE   780 AA;  85018 MW;  0D686CE074E9626D CRC64;
     MAAVDLEKLR ASGAGKAIGV LTSGGDAQGM NAAVRAVTRM GIYVGAKVFL IYEGYEGLVE
     GGENIKQANW LSVSNIIQLG GTIIGSARCK AFTTREGRRA AAYNLVQHGI TNLCVIGGDG
     SLTGANIFRS EWGSLLEELV AEGKISETTA RTYSHLNIAG LVGSIDNDFC GTDMTIGTDS
     ALHRIMEVID AITTTAQSHQ RTFVLEVMGR HCGYLALVSA LASGADWLFI PEAPPEDGWE
     NFMCERLGET RSRGSRLNII IIAEGAIDRN GKPISSSYVK DLVVQRLGFD TRVTVLGHVQ
     RGGTPSAFDR ILSSKMGMEA VMALLEATPD TPACVVTLSG NQSVRLPLME CVQMTKEVQK
     AMDDKRFDEA TQLRGGSFEN NWNIYKLLAH QKPPKEKSNF SLAILNVGAP AAGMNAAVRS
     AVRTGISHGH TVYVVHDGFE GLAKGQVQEV GWHDVAGWLG RGGSMLGTKR TLPKGQLESI
     VENIRIYGIH ALLVVGGFEA YEGVLQLVEA RGRYEELCIV MCVIPATISN NVPGTDFSLG
     SDTAVNAAME SCDRIKQSAS GTKRRVFIVE TMGGYCGYLA TVTGIAVGAD AAYVFEDPFN
     IHDLKVNVEH MTEKMKTDIQ RGLVLRNEKC HDYYTTEFLY NLYSSEGKGV FDCRTNVLGH
     LQQGGAPTPF DRNYGTKLGV KAMLWLSEKL REVYRKGRVF ANAPDSACVI GLKKKAVAFS
     PVTELKKDTD FEHRMPREQW WLSLRLMLKM LAQYRISMAA YVSGELEHVT RRTLSMDKGF
//
